Agendia
The company develops genomic testing platforms, specifically MammaPrint and BluePrint, to analyze tumor biology in early-stage breast cancer patients. These molecular diagnostic tools assess the risk of cancer recurrence and identify molecular subtypes to help physicians personalize treatment plans. The services aim to assist healthcare providers in determining the necessity of chemotherapy and other endocrine treatments to avoid over- or under-treatment.
Visit websiteAmsterdam, Netherlands
Healthtech
Biotech
Oncology
Diagnostics
Funding summary
- Total raised
- €65.3M
- Funding rounds
- 2
Investors in Agendia
Investors on record for Agendia. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Agendia?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors